caa a22 4500 46907437X CHVBK 20180323132931.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF01741555 doi (NATIONALLICENCE)springer-10.1007/BF01741555 Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia — a phase II study [Elektronische Daten] [S. Lim, A. Newland, S. Kelsey, A. Bell, E. Offerman, C. Rist, D. Gozzard, D. Bareford, M. Smith, A. Goldstone] Summary: A group of 13 patients with acute myeloid leukaemia of differing disease status were treated with continuous intravenous infusion of high-dose recombinant interleukin-2 (rIL-2). There was up-regulation of the cellular cytotoxic functions in all these patients following the rIL-2 therapy, with increase in the natural killer (NK) activity, lectin-dependent cellular cytotoxicity, induction of cytotoxicity-linked cytoplasmic serine esterase and lymphocyte activation. However, the clinical response to rIL-2 in these patients was disappointing, especially in patients treated in frank relapse. Although 1 patient treated in early second relapse achieved a third complete remission, the duration of the remission was brief and lasted only 6 months. Adverse reactions among these patients were common. Whether or not lymphokine-activated killer cells are needed to improve the response rate over rIL-2 alone in these patients deserves further investigation. Springer-Verlag, 1992 Acute myeloid leukaemia nationallicence Recombinant interleukin-2 nationallicence Lim S. Department of Haematology, University College Hospital, London, UK aut Newland A. Department of Haematology, The Royal London Hospital, London, UK aut Kelsey S. Department of Haematology, The Royal London Hospital, London, UK aut Bell A. Department of Haematology, Royal Victoria Hospital, Bournemouth, UK aut Offerman E. Department of Haematology, Queen Mary Hospital, Sidcup, UK aut Rist C. Department of Haematology, Worthing Hospital, Worthing, UK aut Gozzard D. Department of Haematology, Glen Clwyd Hospital, Clwyd, UK aut Bareford D. Department of Haematology, Dudley Road Hospital, Birmingham, UK aut Smith M. Department of Haematology, University College Hospital, London, UK aut Goldstone A. Department of Haematology, University College Hospital, London, UK aut Cancer Immunology, Immunotherapy Springer-Verlag 34/5(1992-09-01), 337-342 0340-7004 34:5<337 1992 34 262 https://doi.org/10.1007/BF01741555 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741555 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lim S. Department of Haematology, University College Hospital, London, UK aut NATIONALLICENCE 700 1- Newland A. Department of Haematology, The Royal London Hospital, London, UK aut NATIONALLICENCE 700 1- Kelsey S. Department of Haematology, The Royal London Hospital, London, UK aut NATIONALLICENCE 700 1- Bell A. Department of Haematology, Royal Victoria Hospital, Bournemouth, UK aut NATIONALLICENCE 700 1- Offerman E. Department of Haematology, Queen Mary Hospital, Sidcup, UK aut NATIONALLICENCE 700 1- Rist C. Department of Haematology, Worthing Hospital, Worthing, UK aut NATIONALLICENCE 700 1- Gozzard D. Department of Haematology, Glen Clwyd Hospital, Clwyd, UK aut NATIONALLICENCE 700 1- Bareford D. Department of Haematology, Dudley Road Hospital, Birmingham, UK aut NATIONALLICENCE 700 1- Smith M. Department of Haematology, University College Hospital, London, UK aut NATIONALLICENCE 700 1- Goldstone A. Department of Haematology, University College Hospital, London, UK aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 34/5(1992-09-01), 337-342 0340-7004 34:5<337 1992 34 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer